Researchers from NYU Langone Health and NYU Grossman School of Medicine are part of a major undertaking that will bring together more than 40 scientists, doctors, and industry experts from around the ...
Hosted on MSN20h
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaMALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback